Company profile
Aurinia Pharmaceuticals Inc.
NASDAQ: AUPH · Healthcare · Biotechnology
Canadian filerHQ Edmonton, BCCIK 0001600620Reports USD
#254 of 1,417 Healthcare companies by revenuetop-decile growth
EA Score
78B+FH 93DQ 61GM 69SS 69
v0.1 · 65/100 weight · provisional
↑ net margin, return on assets · ↓ growth stability, disclosure history
Methodology →Revenue TTM
$298.3M
Rev growth YoY (TTM)
+20.6%
Net income (FY)
$287.2M
Employees
128
as of 2026-08-09
Market cap
$2.0B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$283.1M$283.1M2025
Net income$287.2M$287.2M2025
Operating income$104.9M$104.9M2025
Total assets$751.6M$751.6M2025
Liabilities$170.3M$170.3M2025
Equity$581.3M$581.3M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY24
FY24
FY25
FY25
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product96%
License, Collaboration and Royalty Revenue4%
By geography
UNITED STATES93%
JAPAN7%
The read
What is Aurinia Pharmaceuticals Inc.’s revenue?
Aurinia Pharmaceuticals Inc. booked $283.1M in FY2025 revenue, growing 285% year over year — faster than 91% of Healthcare companies we track, at a 101.5% net margin.
Peers · Healthcare
Rigel Pharmaceuticals, Inc.81B+AngioDynamics, Inc.72BXeris Biopharma Holdings, Inc.64CAdaptive Biotechnologies Corporation68BVericel Corporation82B+Harrow Health, Inc.73BKey facts
CEOKevin C. Tang
SectorHealthcare
IndustryBiotechnology
HeadquartersEdmonton, BC
ExchangeNASDAQ: AUPH
Employees128
IPO date2014-09-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.